Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:

X Remove topotecan filter topotecan
X Remove methotrexate filter methotrexate
X Remove idelalisib filter idelalisib
X Remove lapatinib filter lapatinib
X Remove liposomal irinotecan filter liposomal irinotecan
X Remove Exceptional Access Program filter Exceptional Access Program

3 Items

ATRAMERCMTRX

Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)
Intent: Palliative, Curative

Funding:

ODB - General Benefit

mercaptopurine

ODB - General Benefit

methotrexate - oral tablets

Exceptional Access Program

tretinoin (ATRA)

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019

CAPELAPA

Cancer Type: Breast
Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Exceptional Access Program

lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria

Exceptional Access Program

lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019